<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02439333</url>
  </required_header>
  <id_info>
    <org_study_id>2015-KE-63</org_study_id>
    <nct_id>NCT02439333</nct_id>
  </id_info>
  <brief_title>Prospective Randomized Study of Nasal High Flow in Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Li Xuyan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main oxygen therapy to the patients with acute exacerbation of Chronic obstructive&#xD;
      pulmonary disease, who are mild to moderate respiratory insufficiency (arterial blood gas&#xD;
      analysis showed pH = 7.35, PO2 &lt; 60mmHg,PaCO2&gt;45mmHg) or have achieved the traditional&#xD;
      noninvasive ventilation support standard but can not tolerate or reject, was nasal catheter,&#xD;
      venturi mask and other conventional oxygen therapy. All these inaccurate inhaled oxygen&#xD;
      concentration methods with inadequate heating and humidifying lead to poor patient tolerance&#xD;
      and adverse reactions such as airway secretions discharge disorders. The high flow nasal&#xD;
      respiratory therapy (Nasal high flow, NHF) utilises higher gas flow rates than conventional&#xD;
      low-flow oxygen systems. The devices used deliver heated and humidified oxygen at a flow of&#xD;
      up to 60 litres per minute via nasal cannulas with low level continous positive airway&#xD;
      pressure. This study is a prospective randomized study. AECOPD patients with no severe&#xD;
      respiratory failure are treated with NHF and conventional oxygen therapy respectively. The&#xD;
      target is that NHF can increase the comfort degree of patients,reduce the rate of&#xD;
      endotracheal intubation, and shorten the time of hospitalization.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">July 15, 2019</completion_date>
  <primary_completion_date type="Actual">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment failure criteria</measure>
    <time_frame>5 days</time_frame>
    <description>Patients with mild respiratory acidosis (7.25 &lt; pH &lt; 7.35) with obvious dyspnea (accessory respiratory muscle involvement, breathing rate greater than 25 beats per minute)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs of hospitalization expenses</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">320</enrollment>
  <condition>Lung Diseases, Obstructive</condition>
  <arm_group>
    <arm_group_label>Nasal high flow therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AECOPD patients with no severe respiratory insufficiency are given NHF therapy for at least 15 hours per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional oxygen therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AECOPD patients with no severe respiratory insufficiency are given conventional oxygen therapy such as nasal catheter or venturi mask for at least 15 hours per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nasal high flow cannula (Fisher &amp; Paykel Healthcare, Auckland, New Zealand)</intervention_name>
    <description>Nasal high flow therapy</description>
    <arm_group_label>Nasal high flow therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>nasal catheter or Venturi mask</intervention_name>
    <description>Conventional oxygen therapy</description>
    <arm_group_label>Conventional oxygen therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  AECOPD patients.&#xD;
&#xD;
          -  The results of blood gas analysis showed pH â‰¥7.35, PO2&lt; 60mmHg, PaCO2&gt; 45mmHg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The study case has been incorporated into the hospital again.&#xD;
&#xD;
          -  Refused to the NHF therapy.&#xD;
&#xD;
          -  The Glasgow score &lt; 8.&#xD;
&#xD;
          -  Severe organ dysfunction (including liver and kidney dysfunction, decompensated&#xD;
             acidosis, upper gastrointestinal bleeding, DIC, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bing Sun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chao Yang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of respiratory and critical care medicine,Beijing Chao-yang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 7, 2015</study_first_submitted>
  <study_first_submitted_qc>May 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2015</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Li Xuyan</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>Acute exacerbation of chronic obstructive pulmonary disease</keyword>
  <keyword>Nasal high flow therapy</keyword>
  <keyword>Oxygen therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

